STRATEGY for Security

In an interview, Martin VanTrieste, VP quality at Amgen, and Rx-360 spokesperson, talked about Rx-360. VanTrieste feels that a lot of organizations are already working on protecting the product from the pharmaceutical company to the patient, but no one was really paying attention to the upstream pie...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical Executive 2009-12, Vol.29 (12), p.54
Main Author: Koroneos, George
Format: Article
Language:English
Subjects:
Audits
Consortia
Contamination
Counterfeiting
Criminals
Fines & penalties
Good Manufacturing Practice
Hogs
Manufacturing
Nonprofit organizations
Pandemics
Pharmaceutical industry
Raw materials
Shortages
Suppliers
Supply chain management
Supply chains
Vaccines
VanTrieste, Martin
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In an interview, Martin VanTrieste, VP quality at Amgen, and Rx-360 spokesperson, talked about Rx-360. VanTrieste feels that a lot of organizations are already working on protecting the product from the pharmaceutical company to the patient, but no one was really paying attention to the upstream piece. Rx360 focuses on preventing the next heparin, melamine-type contaminations, economic adulteration of their products, or counterfeiting of raw materials before it gets to the manufacturer. He said the main area on their focus is sharing of information. They are looking at new tools that can help prevent someone from adulterating products in the supply chain, and how to detect adulteration if it occurs. The Rx-360 Consortium's end goal is to help pharmaceutical companies gain more information. Drug firms can then use that information to make better decisions about how to increase the security of the supply chain and better authenticate the products that go through that supply chain.
ISSN:0279-6570
2150-735X